# PTD-DBM: Evidence, Mechanism, Dosing & Legal Status

> A clinical monograph on PTD-DBM — the CXXC5-Dishevelled disrupting peptide engineered to reactivate Wnt/β-catenin signaling for hair regrowth. Strong target biology, mouse-only efficacy, and no human trials.

*Published 2026-06-30 · Updated 2026-07-01 · By Marcus Feld, PharmD, BCPS*

The short answer
PTD-DBM is a mechanistically elegant cell-penetrating peptide that disrupts the CXXC5-Dishevelled interaction to reactivate Wnt/β-catenin signaling, accelerating hair regrowth and wound healing — but **only in mice and cultured cells**. There are **no registered or completed human trials**, so its highest evidence grade is **C (preclinical only)**. It is not FDA-approved, sits outside the compounding pathway, and is prohibited in sport under WADA's S0 catch-all.[1](https://peptidevox.com/#r1)[9](https://peptidevox.com/#r9)

PTD-DBM (Protein Transduction Domain-fused Dishevelled-Binding Motif) is a synthetic peptide engineered at Yonsei University to release a brake on the Wnt/β-catenin pathway and reactivate hair-follicle growth.[1](https://peptidevox.com/#r1)[2](https://peptidevox.com/#r2) Its target biology is genuinely well-validated and its preclinical results are striking; its proof in humans is nonexistent. This monograph separates the two.

*This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. PTD-DBM is an experimental research peptide with no approved human use and no completed human trials; it is sold as a "research chemical, not for human use" and is prohibited in sport. Dosing figures are reported strictly as seen in the published preclinical literature for completeness — never as recommendations. Consult a licensed clinician for any hair-loss concern.*

## What is PTD-DBM and how does it work?

PTD-DBM is a designed decoy peptide that fuses three functional parts: a protein-transduction domain (PTD) — a membrane-penetrating sequence that carries cargo across the lipid bilayer and stratum corneum — connected through a flexible linker to the Dishevelled-binding motif (DBM), the short C-terminal segment of CXXC5 that normally docks onto Dishevelled, plus a terminal lysine conjugated to FITC for visualization in the original work.[2](https://peptidevox.com/#r2) Because it presents the Dvl-binding motif without the rest of CXXC5, it occupies Dishevelled and crowds out the full-length protein. The exact amino-acid sequence is detailed in the primary papers and the associated Yonsei patents but is not listed in secondary encyclopedic sources.[5](https://peptidevox.com/#r5)[12](https://peptidevox.com/#r12)

The target is CXXC-type zinc-finger protein 5 (CXXC5), a negative-feedback regulator of Wnt/β-catenin signaling that acts by binding the PDZ domain of Dishevelled (Dvl).[2](https://peptidevox.com/#r2)[1](https://peptidevox.com/#r1) When CXXC5 is bound to Dvl, downstream Wnt signaling is dampened, β-catenin is not stabilized, and follicle-growth signals are suppressed. Critically for human relevance, CXXC5 is upregulated in the miniaturized hair follicles and arrector pili muscles of human balding scalp, and it suppresses alkaline-phosphatase activity and proliferation in human hair-follicle dermal-papilla cells.[1](https://peptidevox.com/#r1) By competitively binding Dvl, PTD-DBM displaces CXXC5 and lifts the brake, producing stabilization and nuclear accumulation of β-catenin and transcription of Wnt target genes. In dermal fibroblasts the peptide dose-dependently raised β-catenin, α-SMA, collagen I and endothelin-1 while leaving the oncogene markers c-Myc and cyclin D1 unchanged, and Wnt activation was directly confirmed in Axin2-LacZ reporter mice.[2](https://peptidevox.com/#r2) No formal pharmacokinetic data — plasma half-life, systemic absorption, metabolism or clearance — have been published; topical/local delivery is the only route studied.[2](https://peptidevox.com/#r2)

## What is the evidence by indication?

The bottom line up front: there are no human RCTs, cohorts, or registered clinical trials of PTD-DBM for any indication. All efficacy evidence is animal and in-vitro, graded C; human relevance is inferred only from the target's dysregulation in balding human scalp and from cultured human dermal-papilla cells. The PubMed and [ClinicalTrials.gov](https://clinicaltrials.gov/) registries return no completed or registered human trials of the peptide as of 2026.[3](https://peptidevox.com/#r3)

  PTD-DBM evidence by indication

    IndicationBest evidenceGrade

    Hair regrowth (telogen-to-anagen)Depilated mouse skin; CXXC5⁻/⁻ knockouts independently regrow fasterC (preclinical)
    Wound-induced hair follicle neogenesis (WIHN)De novo follicle formation in healing mouse wound bedsC (preclinical)
    Cutaneous / wound healingC3H mice: 42.8% re-epithelialization at day 3 vs 4.9% controls (+ valproic acid)C (preclinical)
    Androgenetic alopecia (mechanistic)Partial reversal of DHT/PGD2 suppression; outperformed by KY19382C / mechanistic
    Human topical "biohacker" useOnline forum/vendor reports; no controlled dataD (anecdote)

The foundational dermatology study showed that disrupting the CXXC5-Dvl interaction with the competitor peptide activated Wnt/β-catenin and accelerated hair regrowth in mice, and that CXXC5⁻/⁻ knockout mice independently showed accelerated regrowth — genetically validating that removing the brake is sufficient.[1](https://peptidevox.com/#r1) The same work demonstrated wound-induced hair follicle neogenesis: peptide treatment promoted formation of entirely new follicles within healing wound beds, a capability conventional hair drugs lack.[1](https://peptidevox.com/#r1) In the wound-healing arm, CXXC5⁻/⁻ mice healed full-thickness dorsal wounds roughly 16-32% faster with about 6.3-fold higher fibroblast collagen deposition and over 4-fold higher β-catenin, and daily topical 100 µM PTD-DBM plus valproic acid 500 mM for 11 days achieved 42.8% re-epithelialization at day 3 versus 4.9% in controls, outperforming an EGF positive control — via an endothelin-1-dependent mechanism reversible by bosentan.[2](https://peptidevox.com/#r2)

A later mechanistic study placed CXXC5 inside the androgen cascade: DHT drives androgen-receptor-mediated PTGDS induction, then PGD2 and BMP signaling upregulate CXXC5, suppressing Wnt/β-catenin and miniaturizing follicles. Topical PTD-DBM (10 mM in 300 µL, every other day) reversed PGD2-induced suppression and partially restored DHT-induced suppression — but it was outperformed by the dual-action small molecule KY19382, which completely restored DHT-suppressed β-catenin by targeting both CXXC5 and GSK-3β.[3](https://peptidevox.com/#r3)[4](https://peptidevox.com/#r4)

Proven vs hyped
Proven in humans: nothing. Hyped: all consumer hair-regrowth claims, which extrapolate from mouse and in-vitro work. Notably, the originating lab pivoted to a dual-action small molecule (KY19382) that beat the peptide in the alopecia model — suggesting PTD-DBM may be a research stepping-stone rather than the lead clinical candidate.[4](https://peptidevox.com/#r4)

## What doses appear in the literature?

Reported strictly as information, not a protocol — and there is no human dose at all. The route in every study is topical, applied to depilated or wounded dorsal mouse skin or used in cell and ex-vivo follicle culture; the PTD module is what allows skin penetration, and no injectable or systemic protocol has been published.[2](https://peptidevox.com/#r2) The wound-healing study in C3H mice applied PTD-DBM 100 µM daily for 11 days, alone and combined with valproic acid 500 mM, with EGF 100 µM as a positive control.[2](https://peptidevox.com/#r2) The androgenetic-alopecia study applied PTD-DBM 10 mM in 300 µL topically every other day in vivo, using PGD2 and DHT as challenge agents.[3](https://peptidevox.com/#r3) Valproic acid acts downstream by inhibiting GSK-3β while PTD-DBM acts upstream at Dvl, so the two combine for greater effect — the same upstream-plus-downstream logic that later motivated the single dual-action molecule KY19382.[1](https://peptidevox.com/#r1)[4](https://peptidevox.com/#r4) Research vials are sold as lyophilized powder requiring reconstitution, with no validated human topical formulation, stability or sterility standard, and online topical use is grade-D anecdote against the products' own "not for human use" labeling.[11](https://peptidevox.com/#r11)

## How safe is PTD-DBM?

Human safety data do not exist; the peptide has never completed a human trial, so its human adverse-event profile, immunogenicity, local irritation, absorption and long-term risk are unknown.[3](https://peptidevox.com/#r3) The reassuring preclinical signal is limited: in the mouse wound study, no abnormal skin phenotype appeared after six months of treatment and the oncogenic markers c-Myc and cyclin D1 were not elevated in any group — encouraging, but mouse data over a short window, not a human safety database.[2](https://peptidevox.com/#r2) The dominant theoretical concern is mechanistic: sustained Wnt/β-catenin activation is a proliferative, pro-angiogenic signal, and aberrant Wnt activity is implicated in several cancers, so chronic activation is a legitimate caution the short mouse studies cannot exclude.[2](https://peptidevox.com/#r2) Pregnancy and lactation are cautioned on developmental and teratogenic grounds (Wnt is central to development; the stacked valproic-acid co-agent is a known teratogen), as is active or prior malignancy; no formal contraindications exist because there is no approved human use.[2](https://peptidevox.com/#r2) In practice, research-chemical purity is an additional real hazard: vials sold "not for human use" can carry impurities, endotoxin, bacteria or heavy metals with no cGMP guarantee.[11](https://peptidevox.com/#r11)

## What is the FDA and WADA status in 2026?

PTD-DBM is not an FDA-approved drug and has no USP monograph. It is not the active ingredient of any approved product and does not appear on the FDA's 503A or 503B compounding bulk-substance lists, so under the agency's 2024 revised compounding policy licensed pharmacies cannot lawfully compound it.[6](https://peptidevox.com/#r6)[8](https://peptidevox.com/#r8) Tellingly, it is absent from the July 23-24, 2026 Pharmacy Compounding Advisory Committee docket — which reviews BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax and Epitalon — underscoring that PTD-DBM sits entirely outside the regulated compounding pathway.[7](https://peptidevox.com/#r7) Commercially it is available only through research-peptide vendors that explicitly label it "research chemical, not for human use," and the CXXC5-Dvl-disruption approach is covered by Yonsei University-originated patents.[11](https://peptidevox.com/#r11)[12](https://peptidevox.com/#r12)

For athletes the picture is clear despite the peptide not being named. The WADA Prohibited List's S0 class — Non-Approved Substances — captures any substance not approved by any governmental regulatory health authority for human therapeutic use and still under preclinical or clinical development.[9](https://peptidevox.com/#r9) A preclinical, unapproved Wnt-activating peptide falls squarely under S0 and is therefore prohibited at all times for athletes in tested sport, with no Therapeutic Use Exemption.[10](https://peptidevox.com/#r10) Distinct named hair or growth peptides such as TB-500 sit under S2; PTD-DBM is not in S2 but is still banned via the S0 catch-all.[9](https://peptidevox.com/#r9)

**Bottom line.** PTD-DBM pairs unusually well-validated target biology with a complete absence of human proof. CXXC5 is a real Wnt brake, it is demonstrably overexpressed in human balding scalp, and disrupting the CXXC5-Dishevelled interaction reactivates Wnt signaling to produce accelerated hair regrowth, true wound-induced follicle neogenesis and faster wound healing in mice. That is the honest ceiling of the evidence — grade C, animal and in-vitro only. A functional, root-cause read is favorable on the target, since addressing the DHT→PGD2→CXXC5 driver upstream is conceptually sound, but the molecule itself remains unproven in people and should be treated as experimental. Regulatory facts here are current as of June 2026; the July 23, 2026 PCAC outcome was pending at the time of writing and should be re-verified after that date.

---
Source: https://peptidevox.com/peptide-encyclopedia/ptd-dbm
Index: https://peptidevox.com/llms.txt · Full text: https://peptidevox.com/llms-full.txt